Abstract
Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 mg/m2 iv in day 5. Patients with progressive, symptomatic recurrent or disseminated disease unresponsive to hormonal and/or isotopic treatment were eligible. Nine patients had an objective response: two long-lasting complete and seven partial responses were observed out of 21 evaluable patients. Stable disease was observed in four additional patients. The median duration of response was 12 months (range, 6–29). The total series experienced a median survival of 11 months (range, 1 to 57), with 2 patients actually disease free. Several histologic types of thyroid carcinoma responded, but the best responses were observed in medullary and anaplastic giant-cell carcinomas. Toxicity was reversible in all but one patient. Of the patients failing on BAP chemotherapy three responded to a four drug second line combination containing vincristine, fluorouracil, BCNU and methotrexate. BAP regime can achieve reasonable palliation, and probably increases survival, in poor-prognosis thyroid cancers.
Similar content being viewed by others
References
Ibanez M.I., Russel W.O., Albares-Saavedra J., Lampertico P., White E.C., Lee Clark R. Thyroid carcinoma-biologic behavior and mortality. Cancer 19: 1039, 1966.
Beanfie J.M., Brown C.L., Doniach I., Richardson J.E. Primary malignant tumors of the thyroid: the relationship between histological classification and clinical behavior. Br. J. Surg. 63: 173, 1981.
Taylor S. Thyroid carcinoma and its treatment. Postgrad. Med. J. 44: 404, 1968.
De Besi P., Fiorentino M.V. Importance of thyroxine in suppressing secretion of thyroid stimulating hormones (letter). Br. Med. J. 284: 1705, 1982.
Schumacher P., Metz R., Bey P., Chesnean A.M. Anaplastic Carcinoma of the Thyroid Gland. Eur. J. Cancer Clin. Oncol. 13: 381, 1977.
Hainan K.E. The non-surgical treatment of thyroid cancer. Br. J. Surg. 62: 769, 1975.
Higby D.J., Wallace H.J. Jr., Albert D.J., Holland J.F. Diamminedichloroplatinum; A phase I study showing responses in testicular and other tumors. Cancer 33: 1219, 1974.
Sako K., Razack M.S., Kalnins I. Chemotherapy for advanced and recurrent squamous cell carcinoma of head and neck with high and low dose cis-diamminedichloroplatinum. Am. J. Surg. 136: 529, 1978.
Spanos G.A., Wolk D., Desner M.R., Khan A., Platt N., Khafif R.A., Cortes E.P. Preoperative chemotherapy for giant cell carcinoma of the thyroid. Cancer 50: 2252, 1982.
Omura G.A., Roberts G.A. Combination therapy of solid tumors using 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), Vincristine, Methotrexate, and 5-Fluorouracil. Cancer 31: 1374, 1973.
Gralla R.J., Itri L.M., Pisko S.E., Squillante A.E., Kelsen D.P., Braun D.W., Bordin L.A., Braun T.J., Young C.W. Antiemetic efficacy of high dose methoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 305: 905, 1981.
Hayat M. Status of chemotherapy for thyroid carcinomas. Ann. Radiol. 20: 807, 1977.
Poster D.S., Bruno S., Penta J., Pina K., Catone R. Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin. Trials 4: 301, 1981.
Di Marco A., Gaetani M., Scarpinato B. Adriamycin (NSC-123, 217): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 53: 33, 1969.
Gottlieb J.A., Hill C.S., Ibanez M.L., Clark R.L. Chemotherapy of thyroid cancer. An evaluation experience with 37 patients. Cancer 30: 848, 1972.
Gottlieb J.A., Stratton Hill C. Chemotherapy of thyroid cancer with adriamycin: Experience with 30 patients. N. Engl. Med. 290: 193, 1974.
Fiorentino M., Grigoletto E., Guglielmi M. Cancer indifferencie du corps Thyroide. Guerison par adriamycine. Nouv. Press Med. 4: 2884, 1975.
Harada T., Nishikawa Y., Suzuki T., Ito K., Baba S. Bleomycin treatment for cancer of the Thyroid. Am. J. Surg. 122: 53, 1971.
Hainan K.E., Bleehan N.M., Brewin T.B., Deeley T.J., Harrison D.F.N., Howland p., Kunkler P.W., Ritchie G.L., Wiltshaw E., Todd I.D.H. Early clinical experience with bleomycin in the United Kingdom in a series of 105 patients. Br. Med. J. 4: 635, 1972.
Droz J.P., Morardet N., Charbord P., Maraninchi D., Hayat M., Parmentier C. Chemotherapy of differentiated thyroid carcinomas. Ann. Radiol. 20: 814, 1977.
Blomgren H., Edsmyr F., Strender L.E. Effect of peplomycin on peripheral lymphocytes. Acta Radiol. Oncol. 20: 113, 1981.
Panettiere F., Coltman C.A. Phase I experience with emetine hydrochloride (nsc 33669) as an antitumor agent. Cancer 27: 835, 1971.
Juret P., Tanguy A., Girard A., Le Talaer J.Y., Abbatucci J.S., Dat-Juong, Le Pecq J.B., Paoletti C. Hydroxy9-methyl 2-ellipticinum acetate (nsc 264-137). Toxicologic study and therapeutic effect in 100 cancers. Nouv. Press Med. 8: 1495, 1979.
Benker G., Dabag S., Reinwein D. Chemotherapy of thyroid carcinoma. Benefits and side effects. In: M. Andreoli, F. Monaco, J. Robbins (Eds.), Advances in Thyroid Neoplasia. Field Educational Italia, Rome 1981, p. 263.
Leeper R.D., Shimaoka K. Treatment of metastatic thyroid cancer. Clin. Endocrinol. Metab. 9: 383, 1980.
Benker G., Hackenberg K., Hoff H.G., Seeber S., Ebke J., Windek R., Reinwein D. Zytostatische Kombinationsbehandlung metastasierender schilddrusenkarzinome mit doxorubicin und bleomycin. Dtsch. Med. Wschr. 102: 1908, 1977.
Sokal M., Harmer C.L. Chemotherapy for anaplastic carcinoma of the thyroid. Clin. Oncol. 4: 3, 1978.
Durie B.G.M., Hellman D., Woolfenden J.M., O’Mara R.O., Kartchner M., Salmon S.E. High risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer Clin. Trials 4: 67, 1981.
Bukowski R.M., Brown L., Weick J.K., Groppe C.W., Purvis J. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am. J. Clin. Oncol. 6: 579, 1983.
Droz J.P., Charbord P., Rougier Ph., Parmentier Cl. Failure of chemotherapy in thyroid cancers. Bull. Cancer (Paris) 68: 350, 1981.
Shimaoka K., Schoenfeld D.A., Lerner H., De Conti R.C., ECOG. A randomized trial of adriamycin versus adriamycin plus cis-diammine-dichloroplatinum in patients with thyroid carcinoma. Proc. Am. Soc. Clin. Oncol. 2: 168, 1983.
Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of Doxorubicin Plus Cisplatin in Advanced Thyroid cancer: A Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 70: 405, 1986.
Hoskin P.L.J. and Harmer C.L. Chemotherapy for thyroid cancer. Radiotherapy and Oncology 10: 187, 1987.
Sikic B.I., Collins J.M., Mimnaugh E.G. Improved therapeutic index of Bleomycin when administered by continuous infusion in mice. Cancer Treat. Rep. 62: 2011, 1978.
Fomasiero A., Daniele O., Paccagnella A., Fosser V., Cartei G., Ferrazzi E., Fiorentino M. Toxicity from Continuous Infusion of High Doses of Bleomycin. Tumori, 66: 607, 1980.
Vogl S.E., Zaravinos T., Kaplan B.H. Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimens of diuresis and hydration. Cancer 45: 11, 1980.
Simioni N., Busnardo B., Girelli M.E., Zorat P.L., Pelizzo M.R., Eccher C., De Besi P., Casara D. Medullary thyroid Carcinoma: Clinical-Epidemiological Study of 62 Patients. J. Endocrinol Invest. (Suppl. 1): 217, 1984.
Busnardo B., Girelli M.E., Simioni N., Zorat P.L., Pelizzo M.R., Eccher C., De Besi P., Fassina A., Casara D. Diagnosis and therapy of medullary carcinomas: survey on 74 patients. In: Jaffiol C., Milhaud G. (Eds).), Thyroid Cancer. Elsevier Science Publ., Amsterdam, 1985, p. 307.
Author information
Authors and Affiliations
Additional information
This work was supported, in part, by a grant of the Regione del Veneto, Ricerca finalizzata su Tumori della Tiroide.
Rights and permissions
About this article
Cite this article
De Besi, P., Busnardo, B., Toso, S. et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14, 475–480 (1991). https://doi.org/10.1007/BF03346846
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346846